| Biomarker ID | 431 |
| PMID | 19242826 |
| Year | 2010 |
| Biomarker | TMPRSS2 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Androgen receptor regulation of biosynthesis and transcription,Androgen receptor proteolysis and transcription regulation |
| Experiment | Clincal Stage (1-2) Vs Clinical Stage 3 |
| Type of Biomarker | Prognostic |
| Cohort | Out of 63 patients, 39 had Clinical stages (1-2) and 24 had Stage 3. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.02 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Results were then normalized using the ratio of TMPRSS2/ b-actin and KLK11/b-actin concentration for each sample |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TMPRSS2 |